



**M3 acquires U.S. Multi-Specialty Clinical Research Site
~ Expanding M3-Wake Research's coverage to Florida ~**

M3, Inc. (Headquarters: Tokyo, Japan; CEO: Itaru Tanimura; URL: <https://corporate.m3.com/>; "M3" below) has announced the acquisition of Multi-Specialty Research Associates ("MSRA" below,) which operates a clinical trial site in Lake City, Florida, through its U.S. entity, M3 Wake Research Associates.

■ **Background**

M3 operates m3.com, a specialized web portal for medical professionals that delivers healthcare related information to its 310,000+ physician members in Japan. Presence outside of Japan includes the U.S., U.K., France, China, Korea and India, with aggressive business expansion overseas that has amassed over 6 million physicians as members across its global platforms. This allows provision of services including marketing support, marketing research, and job placement support that leverage the platform's powerful value as a media channel.

M3's clinical trial business in the U.S. was launched in 2018 through the acquisition of Wake; one of North America's largest leading fully integrated network of clinical research sites and a combined database of over 1,000,000 subjects to date. Wake's board-certified physicians have completed more than 9,100 successful clinical trials in most major curative areas, including Covid-19.

MSRA has served as an innovator and leader in clinical trials from its office location in Lake City, Florida, conducting Phase I-IV clinical trials over a wide range of therapeutic areas, including vaccine research for Covid-19 and other infectious diseases. MSRA works with many leading physicians and have a great reputation in a number of areas including women's health, vaccines, primary care, and gastroenterology.

■ **Expected Synergies**

This acquisition will expand Wake's clinical research network into 23 sites across 9 states. It also enables MSRA to provide even higher quality clinical trial services and further expand its service areas through various synergies with Wake's network.

M3 and Wake will continue to extend the clinical trial network and expand the business across the U.S.

M3 Group's Clinical Trial Facilities

